Drs. Nick Lange and Dave Salerno join us to discuss their team's recently published paper taking an in-depth look at the relationship between obesity and outcomes in patients on belatacept-based immunosuppression. To follow along, their article can be found via the following citation:

Lange NW, King K, Husain SA, Salerno DM, Tsapepas DS, Hedvat J, Yu M, Mohan S. Obesity is associated with a higher incidence of rejection in patients on belatacept: A pooled analysis from the BENEFIT/BENEFIT-EXT clinical trials. Am J Transplant. 2024 Jun;24(6):1027-1034. doi: 10.1016/j.ajt.2024.02.015. Epub 2024 Feb 21. PMID: 38387620.

This episode is a follow-up to our December 2023 clinical debate on immunosuppression dosing in the setting of obesity. If you missed it or need a refresher, we encourage you to listen to that episode as well.